[摘要]：NVC-422 is a first-in-class synthetic stable chlorotaurine exhibiting a broad spectrum of activity against Gram-positive and Gram-negative pathogens, without the potential for developing drug resistance. Nova Bay has named these novel agents Aganocide (R) compounds. The company is developing various nonsystemic formulations of this active agent for use in multiple phase II clinical trials for various indications, including urinary catheter blockage and encrustation (UCBE), conjunctivitis and impetigo. Preclinical and clinical studies demonstrated that NVC-422 has a good safety profile and solution stability. NVC-422 is cidal to pathogens by the oxidative modification of sulfur-containing amino acids, such as methionine and cysteine, resulting in protein inactivation. Pathogens die within minutes after exposure to lethal concentrations of NVC-422, as measured by time-kill assays. Multiple passage studies against pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), show no drug resistance. Its mechanism of action, fast time-kill and no observation of drug resistance uniquely differentiate NVC-422 from traditional antibiotics.
